A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03227224 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

287

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder, Major

Interventions

DRUG: Placebo
DRUG: JNJ-42847922

Sponsor

Janssen Research & Development, LLC